« Previous | Next » | All Messages |  KAL Message Board Home | recommend post |  Ignore Poster

KAL News Callisto Discusses Drug Candidate for Gastro-Intestinal Disease in Audio Interview with BiomedDiscoveries.com; Drug Candidate Being Developed as Treatment for Gastro-Intestinal Diseases

Callisto recently announced receipt of a Notice of Allowance of a patent on SP304 from the US Patent and Trademark Office to treat inflammatory diseases of the bowel and colon cancer. Allowed patents are expected to issue as full patents in the near future. Callisto's SP304 is first-in-class of a new category of compounds called guanylate cyclase receptor agonists that have the potential to revolutionize therapy for gastro-intestinal disease, while presenting virtually no known side effects or toxicity.

Callisto's SP304 drug candidate is designed to help replenish damaged cells in the lining of the colon -- cells that may become cancerous -- to function as therapies for people who have gastro-intestinal diseases such as ulcerative colitis. The drug candidate's market value could potentially be enormous, given the pervasiveness of the conditions that it could help to prevent and treat.

This online streaming audio interview is available free of charge to interested investors by visiting: http://www.BiomedDiscoveries.com.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients. Callisto also has drugs in preclinical development for gastro-intestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus and Streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit www.callistopharma.com.

Compensation and Other Disclosures

BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Callisto pays $12,500 per month through July 2006 and thereafter for so long as Trilogy is retained to provide investor relations services. In connection with its engagement, Trilogy received non-transferable warrants from this company to purchase 1,793,322 shares of common stock for $1.03 per share expiring in July 2008, provided that the warrants are not exercisable to the extent that following exercise Trilogy would beneficially own 5% or more of the outstanding common stock of the company.

Forward-Looking Statements

Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are presented by BiomedDiscoveries.com.